AAAAAA

   
Results: 1-10 |
Results: 10
New sensitive assay of vancomycin in human plasma using high-performance liquid chromatography and electrochemical detection
Authors: Favetta, P Guitton, J Bleyzac, N Dufresne, C Bureau, J
Citation: P. Favetta et al., New sensitive assay of vancomycin in human plasma using high-performance liquid chromatography and electrochemical detection, J CHROMAT B, 751(2), 2001, pp. 377-382
Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens
Authors: Bleyzac, N Souillet, G Magron, P Janoly, A Martin, P Bertrand, Y Galambrun, C Dai, Q Maire, P Jelliffe, RW Aulagner, G
Citation: N. Bleyzac et al., Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens, BONE MAR TR, 28(8), 2001, pp. 743-751
Population pharmacokinetics of amikacin at birth and interindividual variability in renal maturation
Authors: Bleyzac, N Varnier, V Labaune, JM Corvaisier, S Maire, P Jelliffe, RW Putet, G Aulagner, G
Citation: N. Bleyzac et al., Population pharmacokinetics of amikacin at birth and interindividual variability in renal maturation, EUR J CL PH, 57(6-7), 2001, pp. 499-504
Comparison of nonlinear mixed-effect and non-parametric expectation maximisation modelling for Bayesian estimation of carboplatin clearance in children
Authors: Patoux, A Bleyzac, N Boddy, AV Doz, F Rubie, H Bastian, G Maire, P Canal, P Chatelut, E
Citation: A. Patoux et al., Comparison of nonlinear mixed-effect and non-parametric expectation maximisation modelling for Bayesian estimation of carboplatin clearance in children, EUR J CL PH, 57(4), 2001, pp. 297-303
Once-a-day individualized amikacin dosing for suspected infection at birthbased on population pharmacokinetic models
Authors: Labaune, JM Bleyzac, N Maire, P Jelliffe, RW Boutroy, MJ Aulagner, G Putet, G
Citation: Jm. Labaune et al., Once-a-day individualized amikacin dosing for suspected infection at birthbased on population pharmacokinetic models, BIOL NEONAT, 80(2), 2001, pp. 142-147
Rapid and sensitive high-performance liquid chromatographic method, for busulfan assay in plasma
Authors: Bleyzac, N Barou, P Aulagner, G
Citation: N. Bleyzac et al., Rapid and sensitive high-performance liquid chromatographic method, for busulfan assay in plasma, J CHROMAT B, 742(2), 2000, pp. 427-432
Diurnal changes in the pharmacokinetic behavior of amikacin
Authors: Bleyzac, N Allard-Latour, B Laffont, A Mouret, J Jelliffe, R Maire, P
Citation: N. Bleyzac et al., Diurnal changes in the pharmacokinetic behavior of amikacin, THER DRUG M, 22(3), 2000, pp. 307-312
Can we use a Bayesian method to build a pharmacokinetic population in two steps?
Authors: Cabelguenne, D Bleyzac, N Pivot, C Maire, P
Citation: D. Cabelguenne et al., Can we use a Bayesian method to build a pharmacokinetic population in two steps?, THERAPIE, 55(2), 2000, pp. 277-282
Assessment of acyclovir intraindividual pharmacokinetic variability duringcontinuous hemofiltration, continuous hemodiafiltration, and continuous hemodialysis
Authors: Bleyzac, N Barou, P Massenavette, B Contamin, B Maire, P Berthier, JC Aulagner, G
Citation: N. Bleyzac et al., Assessment of acyclovir intraindividual pharmacokinetic variability duringcontinuous hemofiltration, continuous hemodiafiltration, and continuous hemodialysis, THER DRUG M, 21(5), 1999, pp. 520-525
Renal differential ageing process and ofloxacin pharmacokinetics in the elderly
Authors: Corvaisier, S Bleyzac, N De Montclos, M Druguet, M Albrand, G Carret, G Maire, P
Citation: S. Corvaisier et al., Renal differential ageing process and ofloxacin pharmacokinetics in the elderly, THERAPIE, 54(2), 1999, pp. 223-231
Risultati: 1-10 |